Publication:
FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).

No Thumbnail Available
Date
2021-05-01T00:00:00Z
Authors
Authors
Catenacci, Daniel V. T.
Kang, Yoon-Koo
Saeed, Anwaar
Yamaguchi, Kensei
Qin, Shukui
Lee, Keun-Wook
Kim, In-Ho
Oh, Sang Cheul
Li, Jin
Turk, Haci M.
Journal Title
Journal ISSN
Volume Title
Publisher
Research Projects
Organizational Units
Journal Issue

Metrics

Search on Google Scholar

Abstract
Description
Keywords
Citation
Catenacci D. V. T. , Kang Y., Saeed A., Yamaguchi K., Qin S., Lee K., Kim I., Oh S. C. , Li J., Turk H. M. , et al., -FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021
Page Views

0

File Downloads

0

Sustainable Development Goals